An Open Label, Randomised, Two-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Via Respimat B Versus the Combination of the Monoproducts of Tiotropium Via Respimat A and BI 54903 Via Respimat B in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2013
At a glance
- Drugs BI 54903; BI 54903/tiotropium bromide; Tiotropium bromide
- Indications Asthma
- Focus Pharmacokinetics
- 28 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 10 Mar 2011 New trial record